Intelligence · Clinical Pipeline

Janssen-Cilag International N.V Pipeline

All ClinicalTrials.gov programs at Janssen-Cilag International N.V — phase, modality, and trial IDs.

Programs: 161

Quick answer

Janssen-Cilag International N.V has 161 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

A study to evaluate how the body absorbs, breaks down and removes drug as well as safety and tolerability when two drugs are administered together as an injection under the skin to healthy participants.

Janssen-Cilag International N.V.

Healthy Volunteers

phase 1 other active

1 trial
A study to evaluate the safety and tolerability of JNJ-70035108 and to evaluate how long JNJ-70035108 stays in and acts on the body (pharmacokinetics) when given as single and repeated doses to healthy participants

Janssen-Cilag International N.V.

Inflammatory Conditions

phase 1 other active

1 trial
A study to evaluate the safety and tolerability of JNJ-90106848 and to investigate how long JNJ-90106848 stays in and acts on the body (pharmacokinetics) and how the body responds to JNJ-90106848 (pharmacodynamics) when injected into healthy volunteer participants

Janssen-Cilag International N.V.

Inflammatory Conditions

phase 1 other active

1 trial
A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers

Janssen-Cilag International N.V.

Previously treated lymphoma (blood cancer) or solid tumors and NHL

phase 1 other active

1 trial
A three-part trial in healthy volunteers to find out how long icotrokinra stays in and acts on the body when administered as different tablet formulations and under different food conditions

Janssen-Cilag International N.V.

Inflammatory Conditions

phase 1 other active

1 trial
A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet formulations and under different food and water conditions, and to assess the acceptability profile (taste, palatability, and smell) of JNJ-77242113 formulations.

Janssen-Cilag International N.V.

Inflammatory Conditions

phase 1 other active

1 trial
An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen-Cilag International N.V.

Non-Hodgkin lymphoma and chronic lymphocytic leukemia

phase 1 other active

1 trial
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants

Janssen-Cilag International N.V.

Renal Impairment

phase 1 other active

1 trial
Characterization of Immune Response in Participants from a Posdinemab Study

Janssen-Cilag International N.V.

Early Alzheimer's disease

phase 1 other active

1 trial
Citarabina Hikma 2 g/20mL Soluzione Iniettabile, Idarubicin Hikma 1 mg/ml Injektionslösung, Cytarabine 100 mg/ml Solution for Injection or Infusion, Cytarabine 100 mg/ml Solution for Injection or Infusion, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, JNJ-75276617, JNJ-75276617 (G022), Venclyxto 100 mg film-coated tablets, Idarubicin, Venclyxto 100 mg film-coated tablets, JNJ-75276617, JNJ-75276617 (G023), Azacitidine, JNJ-75276617, Citarabina Hikma 500mg/5mL Soluzione I

Janssen-Cilag International N.V.

Acute Myeloid Leukemia

phase 1 small molecule active

1 trial
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs

Janssen-Cilag International N.V.

Non-Hodgkin Lymphoid Malignancies (NHLs)

phase 1 other active

1 trial
Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer

Janssen-Cilag International N.V.

Metastatic colorectal cancer and Gastric cancer

phase 1 other active

1 trial
Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

Janssen-Cilag International N.V.

Mild to Moderate Asthma

phase 1 other active

1 trial
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

Janssen-Cilag International N.V.

Localized Bladder Cancer

phase 1 other active

1 trial
Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Janssen-Cilag International N.V.

Acute myeloid leukemia or Myelodysplastic syndrome

phase 1 other active

1 trial
To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

Janssen-Cilag International N.V.

Metastatic castration-resistant prostate cancer (mCRPC)

phase 1 other active

1 trial
Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

Janssen-Cilag International N.V.

Psoriatic Arthritis

approved small molecule active

1 trial

Frequently asked questions

How many pipeline programs does Janssen-Cilag International N.V have?

161 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Quick answer

A study to evaluate how the body absorbs, breaks down and removes drug as well as safety and tolerability when two drugs are administered together as an injection under the skin to healthy participants.

A study to evaluate the safety and tolerability of JNJ-70035108 and to evaluate how long JNJ-70035108 stays in and acts on the body (pharmacokinetics) when given as single and repeated doses to healthy participants

A study to evaluate the safety and tolerability of JNJ-90106848 and to investigate how long JNJ-90106848 stays in and acts on the body (pharmacokinetics) and how the body responds to JNJ-90106848 (pharmacodynamics) when injected into healthy volunteer participants

A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers

A three-part trial in healthy volunteers to find out how long icotrokinra stays in and acts on the body when administered as different tablet formulations and under different food conditions

An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants

Characterization of Immune Response in Participants from a Posdinemab Study

Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs

Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer

Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

Frequently asked questions

Stay Ahead in Pharma